Spectrum Pharmaceuticals Announces FDA Approval of NDA for EVOMELA (melphalan) for Injection for use in two indications
On March 10, 2016, Spectrum Pharmaceuticals, Inc. (the "Company") received notification from the U.S. Food and Drug Administration of the grant of approval of the Company's New Drug Application for EVOMELATM (melphalan) for Injection for use in two indications: 1) use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and 2) for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.